Cargando…
The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma
BACKGROUND: Progression of disease within 24 months (POD24) is a risk factor for poor survival in follicular lymphoma (FL), and there is currently no optimal prognostic model to accurately predict patients with early disease progression. How to combine traditional prognostic models with new indicato...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327599/ https://www.ncbi.nlm.nih.gov/pubmed/37427106 http://dx.doi.org/10.3389/fonc.2023.1090610 |
_version_ | 1785069660847210496 |
---|---|
author | Hu, Jiaci Gao, Fenghua Zhao, Jin Song, Wenzhu Wang, Yanli Zheng, Yuping Wang, Lieyang Han, Weie Ma, Li Wang, Jingrong Bai, Min Guan, Tao Xi, Yanfeng Zhang, Huilai Qiu, Lixia Su, Liping |
author_facet | Hu, Jiaci Gao, Fenghua Zhao, Jin Song, Wenzhu Wang, Yanli Zheng, Yuping Wang, Lieyang Han, Weie Ma, Li Wang, Jingrong Bai, Min Guan, Tao Xi, Yanfeng Zhang, Huilai Qiu, Lixia Su, Liping |
author_sort | Hu, Jiaci |
collection | PubMed |
description | BACKGROUND: Progression of disease within 24 months (POD24) is a risk factor for poor survival in follicular lymphoma (FL), and there is currently no optimal prognostic model to accurately predict patients with early disease progression. How to combine traditional prognostic models with new indicators to establish a new prediction system, to predict the early progression of FL patients more accurately is a future research direction. METHODS: This study retrospectively analyzed patients with newly diagnosed FL patients in Shanxi Provincial Cancer Hospital from January 2015 to December 2020. Data from patients undergoing immunohistochemical detection (IHC) were analyzed using χ(2) test and multivariate Logistic regression. Also, we built a nomogram model based on the results of LASSO regression analysis of POD24, which was validated in both the training set and validation set, and additional external validation was performed using a dataset (n = 74) from another center, Tianjin Cancer Hospital. RESULTS: The multivariate Logistic regression results suggest that high-risk PRIMA-PI group, Ki-67 high expression represent risk factors for POD24 (P<0.05). Next, PRIMA-PI and Ki67 were combined to build a new model, namely, PRIMA-PIC to reclassify high and low-risk groups. The result showed that the new clinical prediction model constructed by PRIMA-PI with ki67 has a high sensitivity to the prediction of POD24. Compared to PRIMA-PI, PRIMA-PIC also has better discrimination in predicting patient’s progression-free survival (PFS) and overall survival (OS). In addition, we built nomogram models based on the results of LASSO regression (histological grading, NK cell percentage, PRIMA-PIC risk group) in the training set, which were validated using internal validation set and external validation set, we found that C-index and calibration curve showed good performance. CONCLUSION: As such, the new predictive model-based nomogram established by PRIMA-PI and Ki67 could well predict the risk of POD24 in FL patients, which boasts clinical practical value. |
format | Online Article Text |
id | pubmed-10327599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103275992023-07-08 The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma Hu, Jiaci Gao, Fenghua Zhao, Jin Song, Wenzhu Wang, Yanli Zheng, Yuping Wang, Lieyang Han, Weie Ma, Li Wang, Jingrong Bai, Min Guan, Tao Xi, Yanfeng Zhang, Huilai Qiu, Lixia Su, Liping Front Oncol Oncology BACKGROUND: Progression of disease within 24 months (POD24) is a risk factor for poor survival in follicular lymphoma (FL), and there is currently no optimal prognostic model to accurately predict patients with early disease progression. How to combine traditional prognostic models with new indicators to establish a new prediction system, to predict the early progression of FL patients more accurately is a future research direction. METHODS: This study retrospectively analyzed patients with newly diagnosed FL patients in Shanxi Provincial Cancer Hospital from January 2015 to December 2020. Data from patients undergoing immunohistochemical detection (IHC) were analyzed using χ(2) test and multivariate Logistic regression. Also, we built a nomogram model based on the results of LASSO regression analysis of POD24, which was validated in both the training set and validation set, and additional external validation was performed using a dataset (n = 74) from another center, Tianjin Cancer Hospital. RESULTS: The multivariate Logistic regression results suggest that high-risk PRIMA-PI group, Ki-67 high expression represent risk factors for POD24 (P<0.05). Next, PRIMA-PI and Ki67 were combined to build a new model, namely, PRIMA-PIC to reclassify high and low-risk groups. The result showed that the new clinical prediction model constructed by PRIMA-PI with ki67 has a high sensitivity to the prediction of POD24. Compared to PRIMA-PI, PRIMA-PIC also has better discrimination in predicting patient’s progression-free survival (PFS) and overall survival (OS). In addition, we built nomogram models based on the results of LASSO regression (histological grading, NK cell percentage, PRIMA-PIC risk group) in the training set, which were validated using internal validation set and external validation set, we found that C-index and calibration curve showed good performance. CONCLUSION: As such, the new predictive model-based nomogram established by PRIMA-PI and Ki67 could well predict the risk of POD24 in FL patients, which boasts clinical practical value. Frontiers Media S.A. 2023-06-23 /pmc/articles/PMC10327599/ /pubmed/37427106 http://dx.doi.org/10.3389/fonc.2023.1090610 Text en Copyright © 2023 Hu, Gao, Zhao, Song, Wang, Zheng, Wang, Han, Ma, Wang, Bai, Guan, Xi, Zhang, Qiu and Su https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Hu, Jiaci Gao, Fenghua Zhao, Jin Song, Wenzhu Wang, Yanli Zheng, Yuping Wang, Lieyang Han, Weie Ma, Li Wang, Jingrong Bai, Min Guan, Tao Xi, Yanfeng Zhang, Huilai Qiu, Lixia Su, Liping The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
title | The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
title_full | The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
title_fullStr | The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
title_full_unstemmed | The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
title_short | The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
title_sort | prognostic index prima-pi combined with ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327599/ https://www.ncbi.nlm.nih.gov/pubmed/37427106 http://dx.doi.org/10.3389/fonc.2023.1090610 |
work_keys_str_mv | AT hujiaci theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT gaofenghua theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT zhaojin theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT songwenzhu theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT wangyanli theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT zhengyuping theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT wanglieyang theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT hanweie theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT mali theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT wangjingrong theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT baimin theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT guantao theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT xiyanfeng theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT zhanghuilai theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT qiulixia theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT suliping theprognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT hujiaci prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT gaofenghua prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT zhaojin prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT songwenzhu prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT wangyanli prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT zhengyuping prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT wanglieyang prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT hanweie prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT mali prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT wangjingrong prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT baimin prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT guantao prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT xiyanfeng prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT zhanghuilai prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT qiulixia prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma AT suliping prognosticindexprimapicombinedwithki67asabetterpredictorofprogressionofdiseasewithin24monthsinfollicularlymphoma |